Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

CABG surgery - cholesterol lowering intervention - preoperative statins


Related trials

JUPITER, 2008 - rosuvastatin vs placebo

Song, 2008 - vs

SAGE, 2007 - atorvastatin high dose vs pravastatin

METEOR, 2007 - rosuvastatin vs placebo

CORONA, 2007 - rosuvastatin vs placebo

Chello et al., 2006 - preoperative atorvastatin vs placebo

ASPEN, 2006 - atorvastatin vs placebo

SPARCL, 2006 - atorvastatin vs placebo

Patti et al., 2006 - preoperative atorvastatin vs placebo

MEGA, 2006 - pravastatin vs control

IDEAL, 2005 - atorvastatin high dose vs simvastatin

Vascular basis, 2005 - atorvastatin high dose vs lovastatin

TNT, 2005 - atorvastatin high dose vs atorvastatin

PACT, 2004 - pravastatin vs placebo

A to Z, 2004 - simvastatin vs placebo

ESTABLISH, 2004 - atorvastatin vs usual care

REVERSAL, 2004 - atorvastatin high dose vs pravastatin

HPS (sub groups), 2004 - simvastatin vs placebo

CARDS, 2004 - atorvastatin vs placebo

PACT, 2004 - pravastatin vs placebo

ASCOT, 2003 - atorvastatin vs placebo

LIPS (sub groups), 2002 - fluvastatin vs placebo

ALLHAT, 2002 - pravastatin vs usual care

PTT, 2002 - pravastatin vs usual care

PROSPER, 2002 - pravastatin vs placebo



See also:

  • All CABG surgery clinical trials
  • All clinical trials of cholesterol lowering intervention
  • All clinical trials of preoperative atorvastatin
    		•  
     Chello et al. study, 2006 TRC7245 
    download pdf: preoperative atorvastatin | cholesterol lowering intervention for CABG surgery

    Treatments

    Studied treatment preoperative atorvastatin 20 mg/d, started 3 wks before surgery
    Control treatment placebo

    Patients

    Patients elective CABG

    Method and design

    Randomized effectives 20 / 20 (studied vs. control)
    Blinding double blind
    Follow-up duration 7 days


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    atrial fibrillation

    2 / 20
         5 / 20
         0,40 [0,09;1,83]

    myocardial infarction (fatal and non fatal)

    0 / 20
         0 / 20
         classic 1,00 [0,00;246,89]

    All cause death

    0 / 20
         0 / 20
         classic 1,00 [0,00;246,89]

    stroke (fatal and non fatal)

    0 / 20
         0 / 20
         classic 1,00 [0,00;246,89]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    atrial fibrillation 2 / 20 (10,0%) 5 / 20 (25,0%) 0,40 [0,09;1,83]  
    myocardial infarction (fatal and non fatal) 0 / 20 (2,5%) 0 / 20 (2,5%) 1,00 [0,02;47,98]  
    All cause death 0 / 20 (2,5%) 0 / 20 (2,5%) 1,00 [0,02;47,98]  
    stroke (fatal and non fatal) 0 / 20 (2,5%) 0 / 20 (2,5%) 1,00 [0,02;47,98]  
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction (for a follow-up of 7 days)
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    atrial fibrillation 10,00% 25,00% -15,00%

    Meta-analysis of all similar trials:

    cholesterol lowering intervention in CABG surgery for preoperative statins



    Reference(s)

    TrialResults-center ID TRC7245
    Trials register # NA
    • Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agr� F, Carassiti M, Covino E. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery.. Crit Care Med 2006;34:660-7
      Pubmed | Hubmed | Fulltext

    (c) 2004-2016 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels